Rivaroxaban is a new type of oral anticoagulant drug used in clinical practice, which is generally unable to eradicate blood clots, and thrombolytic drugs are needed to eradicate blood clots. In clinical practice, rivaroxaban is mainly used to prevent the formation of deep vein thrombosis and reduce the risk of pulmonary embolism caused by deep vein thrombosis; adults with hip or knee replacement, etc. Rivaroxaban can prevent the formation of blood clots, but does not have the effect of eliminating blood clots. Thrombolytic therapy is needed to eradicate blood clots, and common thrombolytic drugs in the clinic include urokinase, streptokinase and so on, and patients can choose appropriate thrombolytic drugs for thrombolytic therapy under the advice of doctors. The contraindications of rivaroxaban are pregnancy, rivaroxaban allergy, etc. The adverse reactions are gum bleeding, gastrointestinal bleeding and so on. For patients with adverse reactions, it is necessary to immediately contact the attending physician to adjust the medication.